PUBLISHER: DelveInsight | PRODUCT CODE: 1074044
PUBLISHER: DelveInsight | PRODUCT CODE: 1074044
DelveInsight's 'Anorexia nervosa-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the anorexia nervosa, historical and forecasted epidemiology as well as the anorexia nervosa market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The anorexia nervosa market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM anorexia nervosa market size from 2019 to 2032. The Report also covers current anorexia nervosa treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
Anorexia nervosa (AN) is an eating disorder characterized by weight loss or lack of appropriate weight gain in growing children; difficulties maintaining an appropriate body weight for height, age, and stature; and, in many individuals, distorted body image. People with anorexia generally restrict the number of calories and the types of food they eat.
This disorder is characterized by deliberate weight loss, induced and sustained by the patient. It occurs most commonly in adolescent girls and young women, but adolescent boys and young men may also be affected, as many children approaching puberty and older women up to the menopause. The disorder is associated with specific psychopathology whereby a dread of fatness and flabbiness of body contour persists as an intrusive, overvalued idea, and the patients impose a low weight threshold on themselves. There is usually under nutrition of varying severity with secondary endocrine and metabolic changes and disturbances of bodily function. The symptoms include restricted dietary choice, excessive exercise, induced vomiting and purgation, and use of appetite suppressants and diuretic
Eating disorders are not a choice but are serious mental illnesses and can significantly impact all aspects of a person's life - physical, emotional, and social. The earlier an eating disorder is identified and a person can access treatment, the greater the opportunity for recovery or improved quality of life.
No objective test-such as bloodwork or an X-ray-can definitively point to an eating disorder. Instead, a doctor makes the diagnosis based on a person's symptoms. To diagnose anorexia, the doctor will ask about the person's symptoms, and they may also ask family members and other loved ones about their observations. If a doctor believes that a person has anorexia, they will attempt to diagnose the type. One type primarily involves restricting food intake, while another involves episodes of overeating and purging. If the person has experienced at least one of these episodes in the past 3 months, the doctor will likely diagnose binge eating and purging anorexia.
Diagnostic instruments in the form of questionaires are used. Few of them are as follows:
Treatment for anorexia must address both psychological and physical problems. The treatment team should include a mental health professional and a primary care doctor.
Successful treatment usually includes continuous medical care, regular therapy, nutritional counseling, and medication. Although certain antidepressants are sometimes used to treat anorexia, they are not always effective, and no medication is FDA approved to treat it. Doctors should pay attention to bone loss, electrolyte levels in the blood, and heart function. Psychologists and other mental health professionals can help a person let go of self-destructive thoughts and behaviors and adopt a more positive outlook. Support groups of other recovering anorexics -- when properly moderated by a mental health professional -- can also be very helpful. Treatment usually is successful, but it does not work overnight. Long-term psychological and medical attention usually is needed.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of anorexia nervosa, diagnosed prevalent cases of anorexia nervosa and gender-specific diagnosed prevalent cases of anorexia nervosa scenario of anorexia nervosa in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
As per DelveInsight's assessment, for anorexia nervosa, the gender-specific distribution of the disease suggests females at a higher count with 763,335 cases in the 7MM, in 2021.
The epidemiology segment also provides the anorexia nervosa epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the anorexia nervosa report encloses the detailed analysis of anorexia nervosa marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the anorexia nervosa clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.
Psilocybin is a serotonin 2 receptor agonist, being developed by COMPASS Pathways, for treatment-resistant depression, including major depressive disorder, depressive disorders, bipolar depression, body dysmorphic disorder (somatoform disorders in developmental table), and anorexia nervosa. It is an active ingredient in some species of mushrooms, often referred to as 'magic mushrooms. Currently, a Phase II trial is expected to complete in 2022 showing the effect of psilocybin-assisted psychotherapy in patients with AN.
Ketamine has rapid antidepressant effects, which are hypothesized to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis, and synaptogenesis. It is an N-methyl-D-aspartate receptor (NMDAr) antagonist, recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several indications, including obsessive-compulsive, post-traumatic, and substance use disorder, and shows trans diagnostic potential for EDs, particularly among clinical nonresponders.
Anorexia Nervosa (AN) has a diverse genetic disposition as well as is being determined by life phases such as puberty, problems in the family or with peers, trauma, and personality traits such as low self-esteem. It is characterized by extreme food restriction and an intense fear of gaining weight. Treatment usually involves several strategies, including psychological therapy, nutritional counseling, and/or hospitalization.
Treatment plans are tailored to individual needs and may include one or more of the following:
Psychotherapies generally include Family-based treatment (FBT), Eating disorder-focused, Adolescent-focused psychotherapy, and others
Medications such as antidepressants, antipsychotics, or mood stabilizers may also be helpful for the treatment of eating disorders and other co-occurring illnesses such as anxiety or depression. Medications like olanzapine, aripiprazole, and dronabinol are generally used to manage the patients, but there is no standard therapy available. Quetiapine is an atypical antipsychotic that, in low dose, can help with both psychological and physical improvements, with minimal associated side effects, and appears to be a promising candidate for the treatment of AN. Prozac can help with depressive symptoms and potentially with healthy weight maintenance once weight restoration is achieved. Prozac is part of the SSRI family or the selective serotonin uptake inhibitors that assist with increased serotonin levels connected to mood.
This section provides the total anorexia nervosa market size and market size by therapies in the United States.
The total anorexia nervosa market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total anorexia nervosa market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the anorexia nervosa market or expected to get launched in the market during the study period 2019-2032. The analysis covers the anorexia nervosa market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for anorexia nervosa emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitively and market Intelligence analysis of the anorexia nervosa market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.